MASH CALL Initiative for Fast and Reliable Identification and Comparison of Clinical Candidates
Select and compare the best anti-steatotic and anti-fibrotic drug candidates and follow-up with a comprehensive phenotypic analysis
MASH (Metabolic Dysfunction-associated Steatohepatitis, renamed from NASH) is a complex, multi-faceted disease, and the InSphero models are designed to reflect this complexity. Our models empower you to simultaneously assess multiple disease parameters, including steatosis, inflammation, and fibrosis. Consequently, you and your team gain a more comprehensive understanding of your asset's impact and efficacy.
Join our MASH CALL Initiative and leverage our pioneering approach for drug discovery with valuable insights about the:
- Anti-steatotic and anti-fibrotic effects of your compounds
- Comparison with clinical candidates and reference controls
Why MASH Screening with InSphero?
We inspire researchers, worldwide, to reach their full potential so that life changing therapies can ultimately make it into the hands of patients.
Fast and translational MASH phenotypic candidate selection process
Screening of MASH candidates for anti-steatotic, anti-fibrotic efficacy and safety assessment simultaneously
Most cost-effective human pre-clinical model
Improvements of scalability and automation have lead to a significant optimization of cost
Benchmarking with clinical candidates
Direct comparison with existing clinical candidates in the MASH space
Leading to a comprehensive phenotypic analysis follow-up
MASH Screening is only the beginning of the journey to identify successful candidates with extended readouts
MASH Call Process
Compound Submission
Submit your candidates from small molecules, antibodies, peptides to siRNA/ASOs.
Treatment in 3D InSight™ MASH model for efficacy analysis
7 concentration dose range treatment of submitted compounds with positive controls and clinical candidates for phenotypic analysis
Endpoint analysis
Extracellular LDH, intracellular triglycerides and secreted pro-collagen 1 as surrogate markers of toxicology, steatosis and fibrosis respectively
Data analysis
Selection of candidates and comparison to anti-fibrotic and anti-steatotic scores with pre-clinical and clinical candidates
Why our customers joined the MASH CALL Initiative
“For our lead target at Inipharm, a human-centric system is extremely important for proof of concept. InSphero’s primary human liver spheroids under culture conditions that resulted in fibrotic and inflammatory processes was able to reproduce known human genetic phenotypes relating to our target of interest. Additionally, the MASH CALL testing platform was an efficient way for us to assess multiple leads for potential efficacy.”
